• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

23andMe

3D rendering of chromosomes and circular extrachromosomal DNA
MedTech

Wojcicki prevails in 23andMe auction, with final $305M bid

Her $305 million offer topped the previous frontrunner, Regeneron, which bid $256 million to incorporate the DNA tester's assets in its R&D.
Conor Hale Jun 16, 2025 10:40am
23andM3 executive ring the Nasdaq opening bell on the day the company goes public

Anne Wojcicki pushes to reopen 23andMe auction

Jun 2, 2025 10:38am
DNA strand

Regeneron’s $256M bid wins 23andMe bankruptcy auction

May 19, 2025 10:37am
3D rendering of chromosomes and circular extrachromosomal DNA

Anne Wojcicki steps down to bid on 23andMe’s bankruptcy auction

Mar 24, 2025 10:43am
human dna structure with glass helix destroyed

23andMe shutters cancer drug research, lays off 40% of staff

Nov 11, 2024 9:07pm
23andM3 executive ring the Nasdaq opening bell on the day the company goes public

23andMine: Anne Wojcicki aims to take genetics company private

Apr 18, 2024 9:16am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings